Is BioMarin Pharmaceutical Inc. (BMRN) a Buy, Sell, or Hold?
BioMarin Pharmaceutical Inc.
NASDAQ:BMRN
$58.64 USD
-$0.56 (-0.95%)
- Volume
- 1.39M
- Average Volume
- 2.06M
- Market Capitalization
- $11.33B
- P/E Ratio
- 41.89
- Dividend Yield
- 0.00%
- Price Target
- $84.00
- Year High
- $66.28
- Year Low
- $49.26
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $5.81
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Alexander Hardy |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | BMRN |
| CUSIP | 09061G101 |
| CIK | 0001048477 |
| Web | https://www.biomarin.com |
| Phone | 415 506 6700 |
| Currency | USD |
| Employees | 3221 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.23 |
| Payout Ratio | 0.00 |
| Current Ratio | 5.81 |
| Quick Ratio | 4.20 |
| Cash Ratio | 2.80 |
Sales & Book Value
| Annual Sales | $3.22B |
| Price / Sales | 3.50 |
| Cash Flow | 3.98 |
| Price / Cash Flow | 14.78 |
| Price / Book | 1.82 |
Price Target and Rating
| Average Stock Price Forecast | $84.00 |
| High Stock Price Forecast | $120.00 |
| Low Stock Price Forecast | $50.00 |
| Forecast Upside/Downside | -30.19% |
| Consensus Rating | Neutral |
| Rating Score(0-5) | 3 |
| Research Coverage | 41 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $1.8 |
| Trailing P/E Ratio | 41.89 |
| PEG Ratio | -0.85 |
| P/E Growth | -0.85 |
| Net Income | $348.9M |
| Net Margin | 8.29% |
| Pretax Margin | 11.89% |
| Return on Equity | 4.41% |
| Return on Assets | 3.13% |
Financials Score
| AltmanZ Score | 4.00 |
| Piotroski Score | 5.00 |
| Working Capital | 3.81B |
| Total Assets | 8.59B |
| Ebit | 408.59M |
| Market Cap | 11.44B |
| Total Liabilities | 2.38B |
Poll Results
About BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Stock
BioMarin Pharmaceutical Inc. specializes in creating and bringing to market treatments for individuals suffering from severe and often fatal rare disorders and other critical medical conditions. The company currently markets several key pharmaceutical products. Among these are Vimizim, an enzyme replacement therapy targeting mucopolysaccharidosis (MPS) IV type A, a specific lysosomal storage disorder, and Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for individuals with MPS VI. Another notable offering is Kuvan, a unique synthetic oral version of 6R-BH4, prescribed for phenylketonuria (PKU), an inherited metabolic condition. Further expanding its product portfolio, BioMarin provides Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme administered via ... subcutaneous injection to lower blood Phe levels. Also available are Brineura, a recombinant human tripeptidyl peptidase 1 used in treating ceroid lipofuscinosis type 2, a variant of Batten disease; Voxzogo, a daily injectable c-type natriuretic peptide analog for achondroplasia; and Aldurazyme, a refined protein mirroring the naturally occurring human enzyme alpha-L-iduronidase. Beyond its established products, BioMarin has a robust development pipeline. This includes valoctocogene roxaparvovec, an adeno-associated virus vector undergoing Phase III clinical trials for severe hemophilia A. Additionally, BMN 307, an AAV5-mediated gene therapy, is in Phase 1/2 trials, aiming to normalize blood phenylalanine levels in PKU patients, while BMN 255 is also in Phase 1/2 trials for primary hyperoxaluria. Its clientele spans specialty pharmacies, hospitals, international government health bodies, and a network of distributors and pharmaceutical wholesalers. These services reach patients and healthcare providers across the United States, Europe, Latin America, and other global markets. BioMarin maintains strategic licensing and collaborative alliances with partners such as Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. Established in 1996, the company's corporate headquarters are located in San Rafael, California.
FDA Accepts BMRN's sNDA Seeking Full Approval for Voxzogo
2026-07-14 11:46:10
BioMarin's FDA filing for full Voxzogo approval in achondroplasia has been accepted, with a regulatory decision expected by Feb. 28, 2027.
2026-07-13 09:05:00
Application based on long-term safety and efficacy data from three ongoing studies, including adult height and additional clinical outcomes beyond linear growth, including body proportionality and arm span evaluated over long-term follow-up FDA PDUFA target action date of Feb. 28, 2027 SAN RAFAEL, Calif., July 13, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental New Drug Application (sNDA) for VOXZOGO ® (vosoritide) for full approval in children with achondroplasia.
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock
2026-07-01 10:41:23
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
2026-06-16 09:05:00
Data from an investigator-led study showed treatment with VOXZOGO resulted in sustained improvements in growth over three years in children with hypochondroplasia New Phase 1 results also presented for investigational BMN 333 support potential weekly dosing in children with achondroplasia SAN RAFAEL, Calif., June 16, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced new data from studies of VOXZOGO® (vosoritide) in children with hypochondroplasia and the investigational medicine BMN 333 in achondroplasia were presented at ENDO 2026, the Endocrine Society Annual Meeting, in Chicago.
BioMarin (BMRN) Up 0.2% Since Last Earnings Report: Can It Continue?
2026-06-03 12:30:37
BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock?
BioMarin's Voxzogo Meets Goal in Late-Stage Study for Hypochondroplasia
2026-05-21 14:26:22
BMRN's shares rise after Voxzogo hits the main goal in a late-stage hypochondroplasia study, supporting planned FDA filings in 2026.
BioMarin Reveals Dwarfism Study Data, Stock Soars
2026-05-21 14:11:47
BioMarin Pharmaceuticals Inc. (NASDAQ:BMRN) stock is trading higher on Thursday as the company is celebrating positive results from its Phase 3 CANOPY-HCH-3 study for VOXZOGO (vosoritide) in children with hypochondroplasia.
BioMarin's drug shows significant growth gains in children in late-stage trial
2026-05-20 17:20:06
BioMarin Pharmaceutical said on Wednesday its treatment for a rare condition that leads to short stature helped boost growth in children, meeting the main goal of a late-stage study and sending shares up nearly 5% in extended trading.
Frequently Asked Questions
-
What is the current BioMarin Pharmaceutical Inc. (BMRN) stock price?
-
BioMarin Pharmaceutical Inc.(NASDAQ:BMRN) stock price is $58.64 in the last trading session. During the trading session, BMRN stock reached the peak price of $66.28 while $49.26 was the lowest point it dropped to. The percentage change in BMRN stock occurred in the recent session was --0.95% while the dollar amount for the price change in BMRN stock was -$-0.56.
-
BMRN's industry and sector of operation?
-
The NASDAQ listed BMRN is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of BMRN?
-
Alexander Hardy | President, Chief Executive Officer & Director
Ganesh Vedantham | Senior Vice President of Technical Development
Arpit Dave | Executive Vice President, Chief Digital & Information Officer
George Eric Davis | Executive VP, Chief Legal Officer & Secretary
Amy Wireman | Executive Vice President & Chief People Officer -
How many employees does BMRN have?
-
Number of BMRN employees currently stands at 3221. BMRN operates from 770 Lindaro Street, San Rafael, CA 94901, US.
-
Link for BMRN official website?
-
Official Website of BMRN is: https://www.biomarin.com
-
How do I contact BMRN?
-
BMRN could be contacted at phone #415 506 6700 and can also be accessed through its website. BMRN operates from 770 Lindaro Street, San Rafael, CA 94901, US.
-
How many shares of BMRN are traded daily?
-
The average number of BMRN shares traded daily for last 3 months was 2.06M.
-
What is the market cap of BMRN currently?
-
The market value of BMRN currently stands at $11.33B with its latest stock price at $58.64